NSAIDs/Gout/RA/Migraine Flashcards
aspirin
- NSAID, non-selective, prostaglandin synthesis inhibitor
- MOA: reversible COX 1 & 2 inhibitor–> inhibit inflammation, pain, and fever
- uses: pain, fever, inflammation, antithrombotic, cramping, colorectal cancer prevention, Alzheimer’s disease, MI/stroke, anticoagulant
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity, tinnitus, Reye’s syndrome, drug interactions
indomethacin
- NSAID, acetic acid, prostaglandin synthesis inhibitor
- MOA: non-selective COX inhibitor
- use: pain, fever, inflammation, antithrombotic, menstrual cramping, MI/stroke, prevention of colorectal cancer, Alzheimer’s, closure of patent ductus arteriosus
- primary NSAID for gout and ankylosing spondylitis
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity
ketorolac
- NSAID, acetic acid, prostaglandin synthesis inhibitor
- MOA: non-selective Cox inhibitor
- use: pain, fever, inflammation, antithrombotic, menstrual cramping, MI/stroke, prevention of colorectal cancer, Alzheimer’s, closure of patent ductus arteriosus
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity
naproxen
- NSAID, prostaglandin synthesis inhibitor, propionic acid
- MOA: non-selective COX inhibitor
- use: pain, fever, inflammation, antithrombotic, menstrual cramping, MI/stroke, prevention of colorectal cancer, Alzheimer’s, closure of patent ductus arteriosus
- used for gout
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity
oxaprozin
- NSAID
- MOA: non-selective COX inhibitor
- use: pain, fever, inflammation, antithrombotic, menstrual cramping, MI/stroke, prevention of colorectal cancer, Alzheimer’s, closure of patent ductus arteriosus
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity
piroxicam
- NSAID, prostaglandin synthesis inhibitor, oxicam
- MOA: non-selective COX inhibitor
- use: pain, fever, inflammation, antithrombotic, menstrual cramping, MI/stroke, prevention of colorectal cancer, Alzheimer’s, closure of patent ductus arteriosus
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity
sulindac
- NSAID
- MOA: non-selective COX inhibitor
- use: pain, fever, inflammation, antithrombotic, menstrual cramping, MI/stroke, prevention of colorectal cancer, Alzheimer’s, closure of patent ductus arteriosus
- used for gout
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity
celecoxib
- NSAID
- MOA: Cox-2 selective inhibitor
- use: RA and osteoarthritis, analgesic, antipyretic, anti-inflammatory
- less GI adverse effects
- No impact on platelet aggregation
- adverse effects: incidence of CV thrombotic events
etoricoxib
- NSAID
- MOA: cox-2 selective inhibitor
- use: analgesic, antipyretic, anti-inflammatory
- less GI adverse effects
- No impact on platelet aggregation
- adverse effects: incidence of CV thrombotic events
meloxicam
- NSAID
- MOA: prostaglandin synthesis inhibitor, Cox-2 selective inhibitor
- use: analgesic, antipyretic, anti-inflammatory
- less GI adverse effects
- No impact on platelet aggregation
- adverse effects: incidence of CV thrombotic events
acetaminophen
- no anti-inflammatory effect, inhibition of platelet aggregation, or GI tract irritation
- actions: angalgesic, antipyretic
- MOA: unclear
- use: mild-to-moderate pain, post-op pain, children and elderly
- adverse effects: hepatotoxicity at high doses w/ alcohol abuse
- narrow therapeutic index with liver necrosis
salicylic acid
- NSAID, prostaglandin synthesis inhibitor
- MOA: reversible COX 1 & 2 inhibitor–> inhibit inflammation, pain, and fever
- uses: pain, fever, inflammation, antithrombotic, cramping, colorectal cancer prevention, Alzheimer’s disease, MI/stroke, anticoagulant
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity, tinnitus, Reye’s syndrome, drug interactions
ibuprofen
- NSAID, propionic acid
- MOA: non-selective Cox inhibitor, prostaglandin synthesis inhibitor
- use: pain, fever, inflammation, antithrombotic, menstrual cramping, MI/stroke, prevention of colorectal cancer, Alzheimer’s, closure of patent ductus arteriosus
- used for gout
- adverse effects: GI upset (Cox-1 inhibition), GI irritation (inhibition of PGs), platelet inhibition, hepatic and renal toxicity, hypersensitivity
capsaicin
- active spice substance in various chili peppers
- MOA: bind vanilloid receptors heat activated Ca2+ channels on afferent nociceptive neurons–> release of Substance P–> depletes and prevents reaccumulation of Substance P
- use: topically for RA, osteoarthritis, neuralgia, shingles, diabetic neuropathy
NSAID interactions
- displacement of protein binding–> increase free fraction of drug
- diuretics: attenuate effects via action on Na+ transport
- anticoagulants: antithrombotic effect
- GI effects (upset, ulcer, bleeding): anticoagulants (bleeding risk), enhanced effects of alcohol and glucocorticoids
acute gout tx
- NSAIDs: idomethacin, colchicine, ibuprofen, naproxen, or sulindac
- NOT aspirin–>renal retention of uric acid
- corticosteroids (fail w/ NSAID/colchicine)
- intra-articular steroid injection (1 or 2 joints affected or elderly)
colchicin
- primary tx for acute gout before idomethacin
- reduce pain and inflammation w/o altering metabolism or excretion of uric acid
- inhibit leukocyte migration and phagocytosis–> anti-inflammatory
- adverse effects: severe diarrhea, nausea, vomiting
allopurinol
febuxostat
- gout prophylaxis
- MOA: inhibit xanthine oxidase–> block conversion of xanthin to uric acid–> lower uric acid conc.
- use: agents for periods b/t acute gout attacks
- febuxostat more selective and well tolerated
probenecid
sulfinpyrazone
- gout prophylaxis
- uricosuric drugs
- MOA: increase renal clearance of uric acid by inhibiting tubular absorption–> decrease body pool of urate
- adverse effects: GI and kidney stone
- not effective in acute attacks of gout
Treatment of RA
- NSAIDs: 1st line drugs-reduce inflammation and pain
- glucocorticoids: reduce inflammation, dramatic improvement in RA
- disease-modifying anti-rheumatic drugs (DMARDs): reduc inflammation, improve symptoms, slow bone damage
NSAIDs for RA
aspirin, acetaminophen, indomehacin, ibuprofen, naproxen, sulindac, celecoxib, etoricoxib, meloxicam, valdecoxib
methotrexate
- synthetic DMARD
- antimetabolite and antifolate agent
- MOA: inhibit AICAR transformylase–> increase extracellular adenosine–> inhibit T-cell actiavtion
- use: 1st line DMARD for treatment of RA
- adverse effects: myelosuppresion
cyclosporine
- synthetic DMARD
- polypeptide antibiotic
- MOA: inhibit IL-1 and IL-2 receptor production
cyclophosphamide
- synthetic DMARD
- cytostatic/cytotoxic agent
- MOA: cytotoxic cross-link DNA to prevent cell replication
azathioprine
- synthetic DMARD
- cytostatic/cytotoxic agent
- MOA: interferes w/ nucleic acid metabolism/synthesis–> inhibit cell proliferation–> suppress B and T cell function, Ig production, and IL-2 secretion
leflunomide
- synthetic DMARD
- MOA: inhibits ribonucleotid synthesis–> cell cycle arrest
- 1st agent for RA for symptomatic improvement and retardation of structural joint damage
chloroquine
hydroxychlorine
- synthetic DMARD
- anti-malarial agent
- MOA: anti-inflammatory action of drugs in RA unclear
aurothigluclose
auranofin
- synthetic DMARD
- gold compounds
- MOA: alter morphology and functional capabilities of human macrophages
sulfasalazine
- synthetic DMARD
- IgA and IgM rheumatoid factor production increased
etanercept
- biologic DMARD
- anti-TNF agent
- MOA: cytokine receptor fusion protein
infliximab
- biologic DMARD
- anti-TNF agent
- MOA: anti-TNF chimeric monoclonal antibody
anakinra
- biologic DMARD
- IL-1 inhibitor
- MOA: IL-1 cytokine receptor decoy
propranolol
metoprolol
- beta-adrenergic receptor antagonists
- preventive therapy of migraine
- MOA: beta 1 and beta 2 antagonist (pro), beta 1 antagonist (met)
- adverse effects: reduced energy, postural symptoms
- contraindicated in pts w/ asthma
amitriptyline
- preventive therapy of migraine
- antidepressant
- adverse effects: drowsiness
valproic acid
topiramate
- preventive therapy of migraine
- anticonvulsants
- adverse effects: drowsiness, weight gain, tremor, hair loss, hemotological and liver abnormalities, teratogenicity
flunarizine
- preventative therapy of migraine
- Ca-channel blocker
- adverse effects: tiredness, weight gain, depression, parkinsonism
verapamil
- preventative therapy of migraine
- Ca2+ channel blocker
- adverse effects: constipation, leg swelling, atrioventricular conduction distrubances
fluoxetine
- preventive therapy of migraine
- selective serotonin-reuptake inhibitor
- adverse effect: anxiety, insomnia
NSAIDs for migraines
- acute migraine attack
- aspirin, naproxen, ibuprofen, acetaminophen
- avoid overuse: limit drug tx to 2-3 days
meperidine
butorphanol
oxycodone
hydromorphone
- tx of acute migraine attack
- opiate analgesics
- risk of dependence and tolerance (not used much)
- adverse effects: rebound headaches, dizziness, nausea, vomiting, impaired cognitive function
metoclopramide
chlorpromazine
prochlorperazine
- acute migraine attacks
- antiemetics
- adjunctive therapy to combat nausea and vomiting
- MOA: dopamine receptor antagonist (D2)
- metoclopramide also weak 5-HT3 receptor antagonist
ergotamine
dihydroergotamine
- acute migraine attacks
- ergot derivatives
- MOA: stimulation of alpha-adrenergic and 5-HT receptors–> vasoconstriction
- dural and cerebral vessels very sensitive
- cerebral vasoconstriction by agonist effects on neuronal or vascular 5-HT1D receptors
- effective, low cost, high experience
- adverse effects: GI disturbance, potent and sustained vasoconstrictor effect
sumatriptan
zolmitriptan
- acute migraine attack
- the “triptans”
- MOA: selective 5-HT1D and 5-HT1B receptor agonists–> cranial/dural vasoconstriction
- higher cost, resricted on use in CV disease
- adverse effects: mild, nausea, dizziness, drowsiness, muscle weakness
- safety: safe, some angina, MI rare
- tolerability: irritating adverse effects (tingling, warmth in head, neck, chest, and limbs)